Share on Facebook Share on Twitter Email
Answers.com

Panitumumab

 
Drug Info: Panitumumab

Brand names: Vectibix™



Panitumumab injection

What is Panitumumab injection?

PANITUMUMAB (Vectibix™) is a monoclonal antibody. It targets a protein called epidermal growth factor receptor (EGFR). This protein is found on the surface of normal cells (such as skin cells and hair cells) and some types of cancer cells including colorectal cancer and head and neck cancer. Panitumumab works by interfering with how these tumor cells grow and causes these cells to die.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
• lung disease, especially lung fibrosis
• an unusual reaction to panitumumab, hamster protein, other medicines, foods, dyes, or preservatives
• pregnant or trying to get pregnant
• breast-feeding

How should this medicine be used?

This medicine is for infusion into a vein. It is administered in a hospital or clinic setting by a health care professional.

Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed.

What if I miss a dose?

It is important not to miss a dose. Notify your doctor or health care professional if you are unable to keep an appointment.

What drug(s) may interact with Panitumumab?

• some medicines for cancer

Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines, nutritional supplements, or herbal products. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines.

What should I watch for while taking Panitumumab?

In a small number of patients, this medicine has caused or worsened lung disease. If you notice difficulty breathing, increased shortness of breath, or other changes in your breathing, notify your health care provider.

This medicine commonly causes skin reactions including a rash that looks like acne, skin dryness and cracking, redness, swelling and other signs of inflammation that can result in skin infections. These reactions may require treatment with antibiotics. Notify your prescriber if you notice any rash, and especially if it seems to get worse or does not get better. You should wear sunscreen and hats and limit your sun exposure (including exposure in tanning beds) while receiving panitumumab. Sunlight can worsen the skin reactions you may experience while receiving this medicine.

There is a possibility that this medicine could cause harm to an unborn child. If you are pregnant or considering getting pregnant, talk to your health care provider about the risks of panitumumab therapy. Discuss possible methods of birth control.

What side effects may I notice from receiving Panitumumab?

Side effects that you should report to your prescriber or health care professional as soon as possible:
• difficulty breathing or shortness of breath anytime during or after your treatments
• extreme tiredness or weakness
• eye inflammation
• mouth sores
• reactions during infusion of the drug (especially difficulty breathing, chills, wheezing, hives, faintness and/or dizziness)
• skin rash, redness, or severe dry or itchy skin

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):
• constipation
• diarrhea
• fatigue, tiredness, or weakness
• nausea/vomiting
• sores on the inside of your mouth
• stomach pain

Where can I keep my medicine?

This does not apply; you will only receive this medication in your prescriber's office or clinic.

Last updated: 10/3/2006 2:25:00 PM

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Wikipedia: Panitumumab
Top
Panitumumab ?
Monoclonal antibody
Source Human recombinant
Target EGFR
Identifiers
CAS number 339177-26-3
ATC code L01XC08
PubChem  ?
Chemical data
Formula C6398H9878N1694O2016S48 
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life ∼7.5 days (range: 4-11 days)
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Prescription only

Routes intravenous


Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

Panitumumab is manufactured by Amgen and marketed as Vectibix.

Contents

Uses

It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment.[1] Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008 for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".

Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.

In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations.[2]

Mechanism

EGFR is a transmembrane protein. Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor.[3]

Production

Panitumumab is produced by immunization of transgenic mice (XenoMouse), that are able to produce human immunoglobulin light and heavy chains. After immunization of these animals a specific clone of B cells that produced an antibody against EGFR was selected and immortalized in Chinese hamster ovary (CHO) cells. These cells are then used for the full scale manufacture of the 100% human antibody.

Panitumumab vs. cetuximab

Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate antibody-dependent cellular cytotoxicity (ADCC).[4]

References

  1. ^ U.S. Food and Drug Administration [1][dead link]
  2. ^ OncoGenetics.Org (July 2009). "FDA updates Vectibix and Erbitux labels with KRAS testing info". OncoGenetics.Org. http://www.oncogenetics.org/web/fda-updates-vectibix-and-erbitux-labels-with-kras-testing-info. Retrieved 2009-07-20. 
  3. ^ Plunkett, Jack W. (September 30, 2005). Plunkett's Biotech & Genetics Industry Almanac 2006. Plunkett Research, Ltd.. ISBN 1593920334. 
  4. ^ HealthValue: IgG1 & IgG2

Further reading

  • Amado, RG (2008). "Wild-Type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer". J Clin Onco 26 (10): 1626–1634. 
  • Van Cutsem, E (2007). "Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer". J Clin Onco 25 (13): 1658–1664. 



 
 
Learn More
Panitumumab injection
Panitumumab Solution for injection
Panitumumab Solución para inyección

Post a question - any question - to the WikiAnswers community:

 

Copyrights:

Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Panitumumab" Read more